Purpose Elevated serum proinflammatory cytokines are associated with the reduction of cytochrome P450 enzyme (CYP) activity. This study aimed to evaluate the oxycodone pharmacokinetics, central symptoms, and serum proinflammatory cytokines based on cachexia stage in cancer patients. Methods Forty-seven cancer patients receiving extendedrelease oxycodone were enrolled. Predose plasma concentrations of oxycodone and its metabolites were normalized with the daily dose and body weight. The central symptoms and serum level of proinflammatory cytokines were investigated at each cachexia stage. Results The plasma concentrations of oxycodone in patients with cachexia and refractory cachexia were significantly higher than that in patients with precachexia. The metabolic ratio to noroxycodone in patients with cachexia was significantly lower than that in patients with precachexia. The patients with a higher cachexia stage had a higher serum level of interleukin-6 (IL-6), but not tumor necrosis factor-α and interleukin-1β. The serum IL-6 level was correlated with the plasma concentration of oxycodone and inversely with the metabolic ratio to noroxycodone. The incidence of somnolence was not associated with the plasma oxycodone concentration. In contrast, the cachexia stage and its associated serum IL-6 level were correlated with the incidence of somnolence. Conclusions Cancer cachexia raised the plasma exposure of oxycodone through the reduction of CYP3A metabolic pathway. The reduction of CYP3A in cachectic cancer patients was associated with an elevation of serum IL-6. Although cachectic cancer patients with higher serum IL-6 levels had the symptom of somnolence, the alterations in oxycodone pharmacokinetics were not related to the incidence of symptom.
Introduction
Oxycodone is a semi-synthetic opioid analgesic commonly used for the relief of moderate to severe pain. It is metabolized by the hepatic cytochrome P450 (CYP) enzyme system [1] . Ndemethylation of oxycodone by CYP3A to noroxycodone is the primary metabolic pathway, while O-demethylation by CYP2D6 to oxymorphone also occurs. Noroxymorphone is a product of noroxycodone metabolism via CYP2D6 and also a minor metabolite of oxymorphone via CYP3A. Noroxycodone exhibits a weak analgesic potency, whereas oxycodone, oxymorphone, and noroxymorphone possess significant opioid μ1 potency [2] .
Cancer patients were reported to have large interindividual variability in oxycodone pharmacokinetics [3] . The contributions of genetic CYP3A and CYP2D6 polymorphisms to oxycodone metabolism have been described [4, 5] . Our previous report also demonstrated that genetic variants of CYP3A5 and CYP2D6 affected the metabolic pathway of oxycodone, but not the plasma exposure of oxycodone [6] . These findings indicate that the genetic variants do not fully explain the interindividual variability in oxycodone pharmacokinetics.
Most patients with cancer cachexia receive opioid analgesics including oxycodone for cancer pain in clinical settings.
Although the mechanisms of cancer cachexia have not been fully elucidated, the overproduction of proinflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β) plays an important role [7, 8] . Recent studies indicate that a chronic inflammatory condition decreases CYP activity [9] [10] [11] . This reduction of CYP is mediated through the down-regulation of gene transcription by proinflammatory cytokines [12, 13] . Our previous study showed that the higher inflammation-based Glasgow Prognostic Score (GPS) raised the plasma concentration of oxycodone through the reduction of CYP3A in cancer patients [14] . Elevated proinflammatory cytokine levels may be responsible for the interindividual variability in oxycodone pharmacokinetics.
Patients with cachectic cancer experience central symptoms that include depression, somnolence, and delirium [15, 16] . These symptoms may be associated with elevated proinflammatory cytokines or drug treatments such as opioid analgesics. Patients with higher inflammation-based GPS had a higher incidence of somnolence [14, 17] . However, our previous study demonstrated that the plasma concentration of oxycodone was not associated with a higher incidence of somnolence [17] . Proinflammatory cytokines play a significant role in neuropsychiatric disorders [18] . IL-6 and TNF-α lead to an alteration of blood-brain barrier permeability [19, 20] . Proinflammatory cytokines may alter the permeability of oxycodone and its metabolites into the brain in cachectic cancer patients. To date, the relationships between oxycodone pharmacokinetics, central symptoms, and serum proinflammatory cytokines have not been fully clarified at each cachexia stage.
The clinical implications of cancer-related proinflammatory cytokine elevation in pain management using oxycodone have not been fully evaluated in clinical settings. The aim of this study was to evaluate the oxycodone pharmacokinetics, central symptoms, and serum proinflammatory cytokines based on cachexia stage in cancer patients.
Methods Ethics
The study was performed in accordance with the Declaration of Helsinki and its amendments, and the protocol was approved by the Ethics Committee of Hamamatsu University School of Medicine. The patients received information about the scientific aim of the study and each patient provided written informed consent.
Patients and blood sampling
The present study was an observation study (UMIN000020723) conducted at a single site (Hamamatsu University Hospital). A total of 61 Japanese patients treated with oxycodone extendedrelease tablets (OxyContin®; Shionogi & Co., Ltd., Osaka, Japan) twice daily at 08:00 and 20:00 for cancer pain were recruited and 47 were enrolled in the present study. Fourteen patients were excluded based on the following criteria: (1) patients who were being co-treated with an opioid μ1 agonist other than oxycodone; (2) patients who were being co-treated with a potent strong CYP2D6 and CYP3A4 inhibitors and inducers including a selective serotonin reuptake inhibitor, triazole antifungal agent, macrolide antibiotic, carbamazepine, or rifampin; (3) patients who were being co-treated with anticancer drugs or treated within 1 week; (4) patients who were being co-treated with immunosuppressants or antimicrobial drugs; (5) patients with a chronic active inflammatory disease; (6) patients with an active infectious disease; and (7) patients with severe hepatic (serum total bilirubin >2.0 mg/dL) or renal (serum creatinine >2.0 mg/dL) dysfunction. Blood was sampled at 4 days or later after starting oral oxycodone. Blood specimens were drawn into tubes at 12 h after the evening dosing. Blood sampling was rescheduled in patients receiving the rescue medication with oxycodone within 12 h.
Evaluation of cachexia stage
Cachexia stage was classified as precachexia, cachexia, and refractory cachexia, using diagnostic criteria described by Fearon et al. [21] . Patients who have more than 5 % loss of stable body weight over the past 6 months, or body mass index less than 20 kg/m 2 and ongoing weight loss of more than 2 %, but have not entered the refractory stage, were classified as having cachexia. Patients who have a diagnosis of expected survival <3 months, or died within 3 months from their blood sampling, were classified as having refractory cachexia. All others were classified as having precachexia. Inflammation-based staging GPS, reported to reflect the degree of prognosis and cachexia, was also investigated. GPS was determined using serum albumin and C-reactive protein (CRP) levels [22] . Patients with both an elevated CRP level (>1.0 mg/dL) and hypoalbuminemia (<3.5 g/dL) were assigned a GPS of 2. Patients in whom only one or none of these biochemical abnormalities was present were assigned a GPS of 1 or 0, respectively.
Determination of plasma oxycodone and its metabolites
Oxycodone and noroxycodone were kindly donated by Shionogi & Co. Oxymorphone was purchased from Mallinckrodt Inc. (St. Louis, MO, USA). Noroxymorphone was obtained from Cerilliant (Round Rock, TX, USA). Plasma was separated by centrifugation of the blood samples at 1670×g at 4°C for 10 min. Plasma concentrations of oxycodone, oxymorphone, noroxycodone, and noroxymorphone were simultaneously determined by an isocratic liquid chromatography-tandem mass spectrometry [6] . Plasma specimens were deproteinized using acetonitrile including naloxone as an internal standard. The linearities were observed at concentration ranges of 1-120 ng/mL for oxycodone (r > 0.999), noroxycodone (r > 0.999), and noroxymorphone (r > 0.999), and 0.05-8 ng/mL for oxymorphone (r > 0.999) in plasma. The intra-and interassay accuracies were 98.5-99.6 % and 96.3-102.5 % for oxycodone, 97.9-100.8 % and 99.3-102.7 % for oxymorphone, 99.0-100.0 % and 96.7-100.3 % for noroxycodone, and 98.6-100.6 % and 97.4-101.8 % for noroxymorphone, respectively. The intra-and interassay precisions were less than 1.7 and 8.7 % for oxycodone, 4.7 and 9.8 % for oxymorphone, 2.3 and 6.0 % for noroxycodone, and 3.6 and 6.4 % for noroxymorphone, respectively. The lower limits of quantification were 1.0 ng/mL for oxycodone, noroxycodone, and noroxymorphone, and 50 pg/mL for oxymorphone. Their assay accuracies and precisions were 97.2 and 7.6 % for oxycodone, 101.1 and 16.0 % for oxymorphone, 101.7 and 7.3 % for noroxycodone, and 102.0 and 8.4 % for noroxymorphone.
Plasma exposure of oxycodone and its metabolic ratio
Plasma exposures of oxycodone, oxymorphone, noroxycodone, and noroxymorphone were evaluated as the predose plasma concentration normalized with the daily dose of oxycodone and body weight. Metabolic ratios to the oxycodone metabolites were estimated by the predose plasma concentration ratio of oxymorphone or noroxycodone to oxycodone and the ratio of noroxymorphone to oxymorphone or noroxycodone. The O-demethylation of oxycodone to oxymorphone and noroxycodone to noroxymorphone, and the N-demethylation of oxycodone to noroxycodone and oxymorphone to noroxymorphone were defined as CYP2D6-and CYP3A-mediated metabolic pathways, respectively.
Measurement of proinflammatory cytokines
Blood samples were centrifuged at 1670×g at 4°C for 10 min and the serum was stored at −80°C until analysis. The serum levels of IL-6, TNF-α, and IL-1β were measured using commercially available enzyme-linked immunosorbent assay kits from BioLegend Inc. (San Diego, CA, USA). The lower limits of quantification were 1.6 pg/mL for IL-6, 3.5 pg/mL for TNF-α, and 0.5 pg/ mL for IL-1β.
Evaluation of central symptoms
Patients without a change in baseline dose of oxycodone for 4 days were considered to have achieved a steady state. Central symptoms were investigated for 1 week after achievement of the steady state in the present study. The central symptoms evaluated included depression, somnolence, and delirium. The severity of the symptoms was assessed using the grading system of the Common Terminology Criteria for Adverse Events (CTCAE v4.0). The incidence and severity were retrospectively obtained from medical records.
Statistical analysis
All statistical analyses were performed using IBM SPSS statistics ver. 22 (IBM Japan Ltd., Tokyo). The influence of cachexia stage on patient demographic characteristics and plasma concentrations of oxycodone and its metabolites, metabolic ratios to the oxycodone metabolites, and serum levels of proinflammatory cytokines were analyzed using the Kruskal-Wallis test and post hoc Mann-Whitney U test with the Dunn correction. The correlations between the serum level of IL-6 and plasma concentrations of oxycodone and its metabolites or metabolic ratios to the oxycodone metabolites were evaluated using Pearson's test. The Fisher exact probability test and simple logistic regression analysis were performed to evaluate the influence of cachexia stage on the incidence of central symptoms. The influences of the plasma concentrations of oxycodone and its metabolites, and serum level of IL-6 on the incidence of central symptoms were analyzed using the Mann-Whitney U test. All values are expressed as the median and interquartile range (IQR) unless otherwise stated. A P <0.05 was considered to indicate statistical significance. Table 1 shows the demographic characteristics of the patients in this study. Ten patients had precachexia, 24 had cachexia, and 13 had refractory cachexia. The serum levels of CRP in patients with cachexia (P < 0.001) and refractory cachexia (P < 0.001) were significantly higher than that in patients with precachexia. Most patients with refractory cachexia had a GPS of 2. Most patients were diagnosed as the highest cancer stage. The patients had head and neck cancer (n = 16), colorectal cancer (n = 5), pancreatic cancer (n = 5), multiple myeloma (n = 4), lung cancer (n = 3), and other types of cancer (n = 14).
Results

Study population
Influence of cachexia stage on oxycodone pharmacokinetics
No significant differences were observed in the absolute concentrations of the oxycodone and its metabolites between the cachexia stages ( Table 2 ). The median plasma concentration of oxycodone was 92.6 ng/mL per mg/kg in patients with precachexia, 149 ng/mL per mg/kg in patients with cachexia, and 167 ng/mL per mg/kg in patients with refractory cachexia. The plasma concentrations of oxycodone in patients with cachexia (P = 0.042) and refractory cachexia (P = 0.009) were significantly higher than that in patients with precachexia. No significant differences were observed in the plasma concentrations of the oxycodone metabolites between the cachexia stage. The metabolic ratio to noroxycodone in patients with cachexia (P = 0.042) and refractory cachexia (P = 0.063) were lower than Data are expressed as median and interquartile range in parentheses. *P < 0.05 and **P < 0.01, different from the cancer patients with precachexia. # Cancer was staged based on the new 7th Union for International Cancer Control/American Joint Committee on Cancer tumor-node-metastasis system [23] . Four patients with multiple myeloma were excluded from cancer staging because a three-grade staging system was used. These patients were diagnosed as stage III Data are expressed as median and interquartile range in parentheses *P < 0.05 and **P < 0.01, different from the cancer patients with precachexia that in patients with precachexia. In contrast, no significant differences were observed in the metabolic ratios to oxymorphone and noroxymorphone between the cachexia stages.
Relationship between cachexia stage and serum proinflammatory cytokines Table 3 shows the relationship between cachexia stage and serum levels of proinflammatory cytokines. The median and IQR of the serum IL-6 level were 12.0 and 6.6-15.3 pg/mL in patients with precachexia, 31.8 and 17.6-54.0 pg/mL in patients with cachexia, and 45.8 and 28.7-54.2 pg/mL in patients with refractory cachexia, respectively. The serum IL-6 levels in patients with cachexia (P = 0.003) and refractory cachexia (P < 0.001) were significantly higher than that in patients with precachexia. No significant differences were observed in the serum levels of TNF-α and IL-1β between the cachexia stages.
Correlations between serum IL-6 and oxycodone pharmacokinetics Figure 1 shows the correlations between the serum IL-6 level and the plasma concentrations of oxycodone and its metabolites in patients treated with oxycodone. The serum IL-6 level was correlated with the plasma concentration of oxycodone (r = 0.493, P = 0.002). In patients with cachexia and refractory cachexia, the serum IL-6 level was correlated with the plasma concentration of oxycodone (r = 0.332, P = 0.045). In contrast, in patients with precachexia, the serum IL-6 level was not correlated with the plasma concentrations of oxycodone and its metabolites.
Correlation between serum IL-6 and oxycodone metabolism
The serum IL-6 level was inversely correlated with the metabolic ratio to noroxycodone (r = −0.352, P = 0.015). In contrast, the serum IL-6 level was not correlated with the metabolic ratio to oxymorphone. The serum IL-6 level was not correlated with the metabolic ratios to noroxymorphone.
Factors related to central symptoms
One patient had depression (grade I), nine had somnolence, and one had delirium (grade II) in this study population. The severity of the somnolence was grade I in eight patients and grade II in one patient. The incidence of somnolence in patients with refractory cachexia was significantly higher than that with precachexia and cachexia (P = 0.008, odds ratio, 8.86; 95 % confidence interval, 1.77-44.3). Table 4 shows the factors related to the incidence of somnolence. The absolute concentration of oxycodone was significantly associated with the incidence of somnolence (P = 0.019). In contrast, the plasma concentrations of oxycodone and its metabolites were not associated with the incidence of somnolence. The serum IL-6 level was significantly associated with the incidence of somnolence (P = 0.004).
Discussion
The present study evaluated the oxycodone pharmacokinetics, central symptoms, and serum proinflammatory cytokines based on cachexia stage in cancer patients. The cancer patients with a higher cachexia stage had a higher plasma concentration of oxycodone and a higher serum level of IL-6. The serum IL-6 level was also correlated with the plasma oxycodone concentration. Cachexia stage and its associated serum IL-6 levels were associated with the incidence of somnolence. These findings suggest that the elevation of plasma oxycodone in cachectic cancer patients was associated with the elevation of serum IL-6. In addition, the cachectic cancer patients with a higher serum IL-6 had the central symptoms. To the best of our knowledge, this is the first report that has evaluated the influence of proinflammatory cytokines on plasma oxycodone and central symptoms in cachectic cancer patients. The plasma exposure of oxycodone in patients with cachexia or refractory cachexia was higher than that with precachexia. In these cancer patients, the oxycodone concentration increased with the progression of cachexia. Our previous study also demonstrated that patients with a higher inflammation-based GPS had a higher plasma concentration of oxycodone [14, 17] . The inflammation-based GPS was reported to reflect the degree of cachexia in various malignancies [22] . In the present study, the clinical symptom-based cachexia stage defined by Fearon et al. [21] had little effect on the plasma exposures of the oxycodone metabolites. These data suggest that cancer cachexia is responsible for the interindividual variability in plasma exposure of oxycodone but not its metabolites.
The metabolic ratio to noroxycodone in patients with cachexia or refractory cachexia was lower than that with precachexia. Our previous studies also showed that patients with a higher inflammation-based GPS had a lower metabolic ratio to noroxycodone [14, 17] . These data indicate that inflammation decreases the CYP3A metabolism of oxycodone. In the present study, most patients with cachexia or refractory cachexia had a higher inflammation-based GPS. Inflammatory conditions such as rheumatoid arthritis and infection also cause the reduction of CYP3A activity [10, 24] . Although the CYP3A activity was not determined in the present study, the reduction of CYP3A activity may raise the plasma oxycodone in cachectic cancer patients.
IL-6, TNF-α, and IL-1β are key cytokines produced in various types of inflammatory conditions such as cancer cachexia and infection [18, 25, 26] . In the present study, the patients with a higher cachexia stage had the higher serum level of IL-6, but not TNF-α and IL-1β. Although these proinflammatory cytokines down-regulate the expression of CYP3A in vitro, this down-regulation needs the higher levels of proinflammatory cytokines [12, 13] . The serum IL-6 level in cachectic cancer patients may have been increased to one that induced down-regulation of CYP3A4 expression. In contrast, the serum levels of TNF-α and IL-1β observed in this study may be insufficient to down-regulate.
The patients with elevated serum IL-6 had a higher plasma concentration of oxycodone and a lower metabolic ratio to noroxycodone. IL-6 is one of the major proinflammatory mediators implicated in the suppression of CYPs under several pathological conditions including inflammation and infection [27] . Several clinical studies have reported a relationship between the elevation of serum IL-6 and suppression of CYP3A [23, 28] . Tocilizumab, an antihuman IL-6 receptor antibody, reverses IL-6-induced suppression of CYP3A4 activity [24] . These data indicate that serum IL-6 affects the interindividual variability in oxycodone pharmacokinetics through the reduction of hepatic CYP3A in cachectic cancer patients.
A higher cachexia stage was associated with a lower activity of the CYP3A-mediated noroxycodone production pathway, while the cachexia stage did not alter the CYP2D6-mediated oxymorphone production pathway. These data indicate that cancer cachexia decreases the CYP3A activity compared with CYP2D6 activity. Although a recent study focused on the impact of IL-6 on the suppression of CYP3A activity, IL-6 also suppresses the other CYPs in vitro [13, 29] . Several CYPs are not affected by inflammation [13, 29] . CYP3A4 was the most sensitive to suppression by IL-6 with a half maximal effective concentration (EC 50 ) of 3.2 pg/mL, whereas CYP2D6 was not sensitive with an EC 50 of 151 pg/mL in human hepatocytes [29] . In the present study, the median serum IL-6 levels in patients with cachexia and refractory cachexia were 31.8 and 45.8 pg/mL, respectively. These data support that an elevated serum IL-6 level decreases the activity of the noroxycodone production pathway via CYP3A but not CYP2D6.
Cachexia stage affected the central symptoms. In contrast, the plasma concentrations of oxycodone and its metabolites did not alter the incidence of central symptoms, although their absolute values were associated with the incidence of central symptoms. These data indicate that the elevation of plasma oxycodone caused by cancer cachexia does not directly alter the incidence of central symptoms. The progress of cachexia decreases albumin synthesis [22] . Cancer cachexia patients had a lower free fraction of oxycodone; however, the free concentration did not alter the incidence of central symptoms [17] . In the present study, the elevation of serum IL-6 was a s s o c i a t e d w i t h t h e i n c i d e n c e o f s o m n o l e n c e . Proinflammatory cytokines alter the blood-brain barrier permeability [19, 20] . An elevated serum level of IL-6 may elevate the permeability of oxycodone and its active metabolites into the brain or directly affect the central nervous system in cachectic cancer patients. Our study may include the oxycodone non-associated central symptoms such as brain metastasis and concomitant drug-induced central symptoms. The prospective observation would confirm our results.
The severity of liver metastases may be also responsible for the variability in hepatic CYP enzymatic activity in cancer patients. Oxycodone clearance decreases in patients with severe hepatic failure [30] ; however, the present study excluded patients whose serum total bilirubin level was higher than 2 mg/dL. Two patients with refractory cachexia were diagnosed as liver metastases. These data support the finding that the diagnosed and undiagnosed liver metastases do not have a potent effect on oxycodone elimination in this study population.
Our study has a few limitations that need to be addressed. First, the patients enrolled had different types and stages of cancer. Our previous study showed that cancer type did not affect the oxycodone pharmacokinetics or central symptoms [17] . In addition, most enrolled cancer patients were diagnosed as the highest cancer stage (Table 1) . These data indicate that the cancer type and stage did not markedly affect the present findings. Second, the serum IL-6 level was weakly correlated with the plasma oxycodone and metabolic ratio to noroxycodone in the present study. These data mean that approximately 80 % of variations in the plasma oxycodone and its metabolism cannot be explained by the serum IL-6 levels. Analyses including genetic variants of CYP3A5 and CYP2D6 were not performed in this study. CYP3A5 and CYP2D6 genotypes had no effect on the plasma exposure of oxycodone without cachexia staging [6] . Further study including CYP3A5 and CYP2D6 genetic analyses would clarify the relationships between the oxycodone pharmacokinetics and serum proinflammatory cytokines in cachectic cancer patients. Third, the blood sample was collected once in every patient in the present study. The use of just one sampling point for the pharmacokinetic analysis potentially has uncertainties. The population pharmacokinetic approach with multiple sampling points would reveal the source of variation in oxycodone concentration and confirm our results.
The clinical implications of cachexia staging and evaluation of serum IL-6 on pain management using oxycodone have not been fully clarified in cancer patients. Cancer patients with cachexia and a higher serum level of IL-6 have higher plasma exposure of oxycodone and a higher incidence of central symptoms. For these patients, the switching to oxycodone from other opioid analgesics should be carefully observed from the viewpoint of safety.
Conclusions
Cancer cachexia raised the plasma exposure of oxycodone through the reduction of CYP3A metabolic pathway. The reduction of CYP3A in cachectic cancer patients was associated with an elevation of serum IL-6. Although cachectic cancer patients with higher serum IL-6 levels had the symptom of somnolence, the alterations in oxycodone pharmacokinetics were not related to the incidence of symptom.
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